6:09 PM
 | 
Nov 12, 2012
 |  BC Extra  |  Clinical News

Novartis presents Phase II canakinumab data

Novartis AG (NYSE:NVS; SIX:NOVN) presented at the American College of Rheumatology meeting on Monday data from two open-label Phase II trials evaluating canakinumab to treat Familial Mediterranean Fever (FMF) and tumor necrosis factor (TNF)-receptor associated periodic syndrome (TRAPS), respectively. In a Phase II trial in nine patients with colchicine-resistant FMF who...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >